Thanks Bear! Your efforts and contributions are greatly appreciated by me and others I am sure.

I expected that there was far more to the ABBVie compound in terms of the complexity of how these molecules work. I seems fair to say that ABBVie is playing in a similar territory as RVX i.e. selective BET inhibitors.

From a business perspective (as you may have noted in my post) I am trying to flush out/understand (as are most investors I think) why RVX has not been successful in getting financing for both Zenith and RVX at this stage. RVX with apabetalone and phase 3 FDA approved BoM which is 95% complete and 6 positive DSMB reports seems grossly undervalued  particularly in the context of the Beacon NPV assessment at $8+.

On the Zenith side I feel like it is in it's infancy from a research perspective and yet it was born out of RVX and thus has all of the intellectual foundations and lab testing behind it. So I would guess there is some value in it. It would have been nice if zen3694 would have been a hit or at least more clear in the findings but at least it is a work in progress.

I do think it is good news that ABBVie and other big players are experimenting in this area. For me it gives credibility to Dr Wongs long term pursuits. This just might bring in some big money that can handle high risk but Don will need to be able to present the business case to attract these investors.

I guess at the end of the day dispite all of the scientific analysis it will be one clear binary clinical trial result that will be the kicker that generates true interest in either of these companies.

I'd like to see more zen3694 results.

GLTA

Toinv